CXCR4 and breast cancer: A phase I trial (NCT01837095) with CXCR4 antagonist Balixafortide and Eribulin chemotherapy evaluated the safety, tolerability, pharmacokinetics and efficacy in heavily pretreated, relapsed breast cancer patients.